Fangda is an undisputed leader in high-profile and complex mergers and acquisitions in China. Clients engage us on their transactions having strategic importance, regulatory complexity or involving multiple jurisdictions. We are known for our commercial awareness and ability to provide sophisticated judgment, as well as for our outstanding client service.

We have vast experience in the full range of strategic and private equity M&A and commercial transactions, including negotiated deals, public M&A, joint ventures, divestments, take-private deals, distressed transactions and business restructuring. We have in-depth knowledge of a range of regulated industries, such as healthcare, pharmaceuticals, financial services, telecommunications, media and technology.

Clients benefit from our transactional capabilities integrated with our unparalleled expertise in financing, IP, employment, environmental and regulatory practices, including antitrust, data compliance and anti-corruption.


  • Corporate/M&A (PRC Firms) - Band 1
    Chambers Greater China, 2022-2023
  • Corporate/M&A (PRC Firms) - Band 1
    Chambers Asia-Pacific, 2011-2021
  • Corporate and M&A: PRC firms - Tier 1
    The Legal 500 Asia Pacific, 2017-2023
  • M&A - China - Tier 1
    IFLR 1000 Financial Law Firm Rankings, 2010-2023
  • Corporate/M&A – Outstanding
    Asialaw Profiles, 2018-2023
  • M&A Firm of the Year – China
    China Law and Practice, 2016-2021
  • M&A Legal Adviser of the Year
    Mergermarket China M&A Awards, 2020-2021
  • Team of the year: M&A
    IFLR1000 China Awards, 2021
  • Corporate Firm of the Year
    IFLR Asia Awards 2018
  • M&A China Announced Deals (By Deal Count) - Rank 1
    Bloomberg – Global M&A Market Review Legal Rankings, 2017-2022
  • M&A Hong Kong Announced Deals (By Deal Count) – Rank 1
    Bloomberg – Global M&A Market Review Legal Rankings, 2017-2022

"Maintains its leading market position, demonstrating impressive experience in handling big-ticket M&A. Frequently acts on complex, cross-border mandates for an enviable roster of clients, including major domestic corporates and multinationals. Widely admired for the impressive scope of its team and capabilities."

Chambers Asia-Pacific, 2019

Notable Matters

We were the main deal counsel or one of the leading firms of advisors in the following landmark cross-border and domestic M&A or investment transactions:


  • Alibaba on its RMB28.2 billion investment in Suning Commerce Group and Suning’s RMB14 billion investment in Alibaba.
  • Philips on its acquisition of the POVOS kitchen appliance business for RMB2.2 billion.
  • GE on its RMB3.3 billion investment in China XD Electric Co. and joint venture with XD. This was the first successful strategic investment by a U.S. Fortune 500 company in a Chinese-listed company.
  • Swire Beverage on its acquisition of bottling operations from The Coca-Cola Company and COFCO, also involving disposals of some bottling operations to COFCO, at a net cost of RMB4.6 billion.
  • The Hershey Company on its RMB2.4 billion purchase of Shanghai Golden Monkey Food Co.
  • Tyson Foods, Inc. in connection with the Hong Kong and China components of a deal to acquire MFG (USA) Holdings, Inc. and McKey Luxembourg Holdings.
  • Starbucks Corporation on its acquisition of a 50% stake in Shanghai Starbucks Coffee (a JV) for US$1.3 billion.
  • China Resources Enterprise on its acquisition of Tesco’s China retail business and the resulting formation of a joint venture.
  • Envision on its global acquisition of Automotive Energy Supply Corporation (AESC), Nissan’s worldwide car battery business, and on Envision’s joint venture with Nissan in a transaction valued at more than US$1 billion.
  • CITIC Group and its subsidiary CITIC Dicastal Co. on their US$300 million acquisition of KSM Castings
  • Tianjin Tianhai Investment Co., an A-share listed company, on its US$6 billion acquisition of Ingram Micro Inc., a NYSE-listed company.
  • Shanghai Electric Group on its acquisition of a 40% stake in Ansaldo Energia, a power engineering company in Italy, for €400 million.
  • UBS on its US$2 billion pre-IPO investment in Postal Savings Bank of China and on its US$500 million investment in the Bank of China.
  • The Royal Bank of Scotland, as the lead consortium investor, on the US$3.1 billion acquisition of a 10% stake in the Bank of China.
  • Citibank on the US$3 billion acquisition of a stake in Guangdong Development Bank.
  • P. Morgan Securities (Asia Pacific) on its establishment of a joint venture company in China.
  • China Construction Bank on its acquisition of Bankco WestLB do Brasil.
  • Bayer on its acquisition of Dihon Pharmaceutical Group for RMB3.6 billion.
  • China Everbright on its acquisition of 22.4% of the shares in LifeTech, a leading cardiovascular device manufacturer in China.
  • Bluesail Medical Co. on its acquisition of 93% of the shares in Biosensors International, a medical device company, for RMB5.9 billion.